AAV vectors for retinal and CNS gene therapy

Patent metadata

Field	Value
Publication number	US-10982228-B2
Application number	US-201515308335-A
Country	US
Kind code	B2
Filing date	May 2, 2015
Priority date	May 2, 2014
Publication date	Apr 20, 2021
Grant date	Apr 20, 2021

Abstract

Provided herein are improved rAAV (e.g., rAAV2, rAAVrh8R, etc.) for enhanced gene therapy of ocular disorders or CNS disorders wherein the rAAV comprise one or more substitutions of amino acids that interact with heparan sulfate proteoglycan. The invention provides methods for improved transduction of retinal cells and methods for treating ocular diseases with improved compositions of rAAV particles. Further provided herein are improved recombinant adeno-associated virus (rAAV) (e.g., rAAV2, rAAVrh8R, etc.) for enhanced gene therapy of disorders of the CNS. The invention provides methods for delivering the rAAV to the CNS, methods for treating disorders of the CNS with improved compositions of rAAV particles, and kits for delivering the rAAV to the CNS and/or treating a CNS disorder.

First claim

What is claimed is:

1. A method for delivering a heterologous nucleic acid to the eye of an individual comprising administering a recombinant adeno-associated virus (rAAV) particle to the subretina of the individual, wherein administration of the rAAV particle transduces and expresses the heterologous nucleic acid, wherein:
(i) the rAAV particle is an AAV serotype 2 (AAV2) particle comprising:
(a) an AAV2 capsid comprising an AAV2 capsid protein comprising a R585A substitution, a R588A substitution, or R585A and R588A substitutions, numbering based on VP1 numbering of AAV2;
(b) a rAAV vector comprising the heterologous nucleic acid and at least one AAV inverted terminal repeat;

or
(ii) the rAAV particle is an AAV serotype rh8R (AAVrh8R) particle comprising:
(a) an AAVrh8R capsid comprising an AAVrh8R capsid protein comprising a R533A substitution, numbering based on VP1 numbering of AAVrh8R;
(b) a rAAV vector comprising the heterologous nucleic acid and at least one AAV inverted terminal repeat.

2. The method of claim 1 , wherein the rAAV particle is an AAV2 particle comprising an AAV2 capsid.

3. The method of claim 2 , wherein the numbering is based on the VP1 of AAV2 comprising the amino acid sequence of SEQ ID NO: 1.

4. The method of claim 2 , wherein the AAV2 capsid protein comprises amino acid substitutions R585A and R588A, numbering based on VP1 of AAV2.

5. The method of claim 1 , wherein the rAAV particle comprises one or more rAAV capsid proteins having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to SEQ ID NOs:2, 4 and/or 6.

6. The method of claim 1 , wherein the rAAV particle is an AAVrh8R particle comprising an AAVrh8R capsid.

7. The method of claim 1 , wherein the heterologous nucleic acid encodes a therapeutic polypeptide or therapeutic nucleic acid.

8. The method of claim 1 , wherein the heterologous nucleic acid encodes a polypeptide selected from the group consisting of an antioxidant, a neurotrophic factor, an anti-apoptotic factor, an anti-angiogenic factor, and an anti-inflammatory factor.

9. The method of claim 1 , wherein the heterologous nucleic acid encodes a polypeptide selected from the group consisting of: Prph2, RPE65, AIPL1, GUCY2D, LCA5, CRX, CEP290, MYO 7a, Clarin, ABCA4, RDH12, IMPDH1, CRB1, LRAT, NMNAT1, TULP1, MERTK, RPGR, RP2, RPGRIP, CNGA3, CNGB3, GNAT2, GDNF, CNTF, FGF2, PEDF, EPO, BCL2, BCL-X, NFκB, Endostatin, Angiostatin, sFlt, sPDGF-R, IL10, anti-IL17, sIL17R, IL1-ra, anti-TGFβ, sTNF-R I, sTNF-R II, and IL4.

10. The method of claim 1 , wherein the heterologous nucleic acid encodes a therapeutic nucleic acid.

11. The method of claim 10 , wherein the therapeutic nucleic acid is an siRNA, an shRNA, an RNAi, an miRNA, an antisense RNA, a ribozyme or a DNAzyme.

12. The method of claim 1 , wherein the heterologous nucleic acid is under the control of a promoter sequence that is expressed in the retina.

13. The method of claim 12 , wherein the promoter is a rhodopsin kinase (RK) promoter, an opsin promoter, a Cytomegalovirus (CMV) promoter, a chicken β-actin (CBA) promoter.

14. The method of claim 1 , wherein the heterologous nucleic acid is operably linked to a promoter suitable for expression of the therapeutic polypeptide or therapeutic nucleic acid in one or more retina cell types.

15. The method of claim 14 , wherein the retina cell is a photoreceptor cell, a retinal pigmented epithelial cell, bipolar cell, horizontal cell, amacrine cell, muller cell and/or ganglion cell.

16. The method of claim 14 , wherein the retina cell is a photoreceptor cell.

17. The method of claim 1 , wherein the individual is a human.

18. The method of claim 17 , wherein the heterologous nucleic acid is used to treat an ocular disorder selected from the group consisting of: autosomal recessive severe early-onset retinal degeneration (Leber's Congenital Amaurosis), congenital achromatopsia, Stargardt's disease, Best's disease, Doyne's disease, cone dystrophy, retinitis pigmentosa, X-linked retinoschisis, Usher's syndrome, age related macular degeneration, atrophic age related macular degeneration, neovascular AMD, diabetic maculopathy, proliferative diabetic retinopathy (PDR), cystoid macular oedema, central serous retinopathy, retinal detachment, intra-ocular inflammation, glaucoma, and posterior uveitis.

19. The method of claim 1 , wherein the rAAV vector is a self-complementary rAAV vector.

20. The method of claim 19 , wherein the vector comprises first nucleic acid sequence encoding the heterologous nucleic acid and a second nucleic acid sequence encoding a complement of the nucleic acid, wherein the first nucleic acid sequence can form intrastrand base pairs with the second nucleic acid sequence along most or all of its length.

21. The method of claim 20 , wherein the first nucleic acid sequence and the second nucleic acid sequence are linked by a mutated AAV ITR, wherein the mutated AAV ITR comprises a deletion of the D region and comprises a mutation of the terminal resolution sequence.

22. The method of claim 1 , wherein the rAAV particle is in a pharmaceutical composition.

23. The method of claim 22 , wherein the concentration of the rAAV particle in the pharmaceutical composition is about 1×10 6 DRP/ml to about 1×10 14 DRP/ml.

24. The method of claim 22 , wherein the pharmaceutical composition of the rAAV particle is effective in treating the individual's visual function.

25. The method of claim 24 , wherein visual function is assessed by microperimetry, dark-adapted perimetry, assessment of visual mobility, visual acuity, ERG, or reading assessment.

26. The method of claim 24 , wherein the method results in an improvement in the individual's visual function.

27. The method of claim 1 , wherein the method results in the prevention of or a slowing of the progression of decline of the human's visual function due to progression of the ocular disorder.

28. A method for improving rAAV transduction of cells or improving expression of a heterologous nucleic acid following subretinal delivery of a rAAV particle to the eye of an individual,
(i) wherein the rAAV particle is an AAV2 particle, the method comprises incorporating a R585A substitution, a R588A substitution, or R585A and R588A substitutions in an AAV2 capsid protein, numbering based on VP1 numbering of AAV2; or
(ii) wherein the rAAV particle is an AAVrh8R particle, the method comprises incorporating a R533A substitution in an AAVrh8R capsid protein, numbering based on VP1 numbering of AAVrh8R; wherein the rAAV particle comprises the AAV capsid protein and a rAAV vector comprising a heterologous nucleic acid and at least one AAV terminal repeat.

29. The method of claim 28 , wherein the rAAV transduction of cells or the expression of the heterologous nucleic acid following delivery of the rAAV particle to the subretina of the individual is improved compared to transduction of cells or expression of the heterologous nucleic acid with a rAAV particle comprising a wild type capsid protein.

30. The method of claim 28 , wherein the rAAV particle is an AAV2 particle, and wherein the AAV2 capsid comprises an AAV2 capsid protein comprising amino acid substitutions R585A and

Assignees

• Genzyme Corp

Inventors

• Scaria Abraham
• Sullivan Jennifer

Classifications

• C12N2750/14145

  Special targeting system for viral vectors · CPC title

• C12N2750/14143

  viral genome or elements thereof as genetic vector · CPC title

• C12N2750/14122

  New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes · CPC title

• C12N15/86 Primary

  Viral vectors · CPC title

• C07K14/71

  for growth factors; for growth regulators · CPC title